• Our Company

QuintilesIMS Delivers Integrated Information and Technology Solutions to Drive Healthcare Forward

Around the world healthcare stakeholders are working to improve real-world patient outcomes through treatment innovations, care provision and access to healthcare. For the information, technology and service solutions they need to drive new insights and approaches, they count on QuintilesIMS. With a global team of 50,000, we harness insights, commercial and scientific depth, and executional expertise to empower clients to achieve some of their most important goals: Improving clinical, scientific and commercial results. Realizing the full potential of innovations. And, ultimately, driving healthcare forward.

For more information please visit www.quintilesims.com.

Driving Performance in Hungary

Since its establishment in 1991, QuintilesIMS Hungary has achieved the position of a trusted advisor and leader in providing insights into the pharmaceutical market. QuintilesIMS Hungary has one of the most comprehensive offering portfolios in the region, with solutions for the life sciences industry including prescription data, sell-out services and patient level analytics.

In 2008, QuintilesIMS Hungary made a significant investment to deliver more accurate data for measuring final drug consumption levels and introduced a sell-out offering.

Since 2013, as a result of further developments in the utilization of longitudinal patient level data, QuintilesIMS Hungary has supported clients with a deep understanding of patient dynamics to identify appropriate patient segments and tailor strategic decisions. Anonymized longitudinal patient level information provides a powerful patient lens to drive focus and alignment across business; deepening the understanding of critical patient, physician and payer dynamics.

For over two decades QuintilesIMS Hungary has been monitoring the changes and development of the national market. In 2012, the Hungarian pharmaceutical market reached €2.1 billion (retail and hospital), contracting by close to 3 %, as a result of austerity measures. Currently 412 manufacturer groups operate in the Hungarian pharmaceutical market, with 10 corporations, including the two largest local manufacturers EGIS and Gedeon Richter, accounting for 56% of the total sales value. Generics are dominating the market with close to a 60% share of volume in 2012, while original products still hold 53% of the pharmaceutical market in value. The top therapy areas in 2012 were antineoplastic and cardiovascular.